Free Trial
TSE:ONC

Oncolytics Biotech 11/12/2024 Earnings Report

Oncolytics Biotech logo
C$0.73 -0.02 (-2.67%)
As of 03:59 PM Eastern

Oncolytics Biotech EPS Results

Actual EPS
-C$0.12
Consensus EPS
-C$0.11
Beat/Miss
Missed by -C$0.01
One Year Ago EPS
-C$0.14

Oncolytics Biotech Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Oncolytics Biotech Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Oncolytics Biotech Earnings Headlines

Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
Oncolytics Biotech Inc.
Oncolytics price target lowered to C$5 from C$6 at RBC Capital
See More Oncolytics Biotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Oncolytics Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oncolytics Biotech and other key companies, straight to your email.

About Oncolytics Biotech

Oncolytics Biotech (TSE:ONC), a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

View Oncolytics Biotech Profile

More Earnings Resources from MarketBeat